cyclerion therapeutics, inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. its product candidates include olinciguat, an orally administered vascular soluble guanylate cyclase (sgc) stimulator that is in phase ii studies for the treatment of sickle cell disease (scd); praliciguat, an orally administered systemic sgc stimulator that is in phase ii trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and iw-6463, an orally administered central nervous system (cns)-penetrant sgc stimulator, which is in phase i trials for neurodegenerative diseases. the company is also discovering liver-targeted sgc and lung-targeted sgc stimulators. cyclerion therapeutics, inc. was incorporated in 2018 and is headquartered in cambridge, massachusetts.
Company profile
Ticker
CYCN
Exchange
Website
CEO
Peter M. Hecht
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
831895370
CYCN stock data
Latest filings (excl ownership)
8-K
Other Events
18 Apr 24
10-K
2023 FY
Annual report
5 Mar 24
UPLOAD
Letter from SEC
28 Dec 23
CORRESP
Correspondence with SEC
12 Dec 23
8-K
Cyclerion Appoints Regina Graul, Ph.D., as President
4 Dec 23
8-K
Cyclerion Strengthens Board of Directors with Experienced Company Builder
1 Dec 23
UPLOAD
Letter from SEC
28 Nov 23
8-K
Departure of Directors or Certain Officers
24 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Departure of Directors or Certain Officers
23 Oct 23
Latest ownership filings
3
RHONDA M. CHICKO
11 Mar 24
SC 13G/A
TYNDALL CAPITAL PARTNERS L P
14 Feb 24
SC 13G/A
Artal International S.C.A.
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Peter M Hecht
26 Jan 24
4
Regina Margaret Graul
26 Jan 24
SC 13G/A
Slate Path Capital LP
22 Jan 24
3
Dina Katabi
11 Dec 23
3
Michael J Higgins
7 Dec 23
3/A
Regina Margaret Graul
7 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.11 mm | 9.11 mm | 9.11 mm | 9.11 mm | 9.11 mm | 9.11 mm |
Cash burn (monthly) | (no burn) | 941.42 k | 2.01 mm | 3.97 mm | 2.31 mm | 2.23 mm |
Cash used (since last report) | n/a | 6.26 mm | 13.34 mm | 26.38 mm | 15.38 mm | 14.83 mm |
Cash remaining | n/a | 2.85 mm | -4.23 mm | -17.27 mm | -6.27 mm | -5.72 mm |
Runway (months of cash) | n/a | 3.0 | -2.1 | -4.4 | -2.7 | -2.6 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 22 |
Opened positions | 2 |
Closed positions | 3 |
Increased positions | 3 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 3.20 bn |
Total shares | 9.90 mm |
Total puts | 0.00 |
Total calls | 100.00 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
MFN Partners | 3.39 mm | $5.83 mm |
Artal International S.C.A. | 2.78 mm | $4.78 mm |
American Endowment Foundation | 2.66 mm | $8.14 mm |
Slate Path Capital | 357.88 k | $1.22 bn |
MFN Partners Management | 169.46 k | $576.16 mm |
FMR | 164.55 k | $559.47 mm |
Tyndall Capital Partners L P | 147.71 k | $505.18 mm |
Artal | 138.40 k | $473.00 k |
Vanguard | 40.53 k | $138.62 mm |
Geode Capital Management | 30.75 k | $104.58 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Jan 24 | Regina Margaret Graul | Common Stock | Grant | Acquire A | No | No | 0 | 50,000 | 0.00 | 100,303 |
1 Jan 24 | Hecht Peter M | Common Stock | Grant | Acquire A | No | No | 0 | 15,000 | 0.00 | 377,385 |